Shi Liqin, Ren Jiahao, Wang Yujia, Feng Huifen, Liu Fang, Yang Haiyan
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China.
School of Nursing, Hebi Polytechnic, Hebi 458030, China.
Vaccines (Basel). 2022 Dec 30;11(1):89. doi: 10.3390/vaccines11010089.
We aimed to explore the influence of comorbid asthma on the risk for mortality among patients with coronavirus disease 2019 (COVID-19) in Asia by using a meta-analysis. Electronic databases were systematically searched for eligible studies. The pooled odds ratio (OR) with 95% confidence interval (CI) was estimated by using a random-effect model. An inconsistency index (I2) was utilized to assess the statistical heterogeneity. A total of 103 eligible studies with 198,078 COVID-19 patients were enrolled in the meta-analysis; our results demonstrated that comorbid asthma was significantly related to an increased risk for COVID-19 mortality in Asia (pooled OR = 1.42, 95% CI: 1.20−1.68; I2 = 70%, p < 0.01). Subgroup analyses by the proportion of males, setting, and sample sizes generated consistent findings. Meta-regression indicated that male proportion might be the possible sources of heterogeneity. A sensitivity analysis exhibited the reliability and stability of the overall results. Both Begg’s analysis (p = 0.835) and Egger’s analysis (p = 0.847) revealed that publication bias might not exist. In conclusion, COVID-19 patients with comorbid asthma might bear a higher risk for mortality in Asia, at least among non-elderly individuals.
我们旨在通过荟萃分析探讨合并哮喘对亚洲2019冠状病毒病（COVID-19）患者死亡风险的影响。系统检索电子数据库以查找符合条件的研究。采用随机效应模型估计合并95%置信区间（CI）的合并比值比（OR）。使用不一致指数（I2）评估统计异质性。共有103项符合条件的研究、198,078例COVID-19患者纳入荟萃分析；我们的结果表明，在亚洲，合并哮喘与COVID-19死亡风险增加显著相关（合并OR = 1.42，95% CI：1.20−1.68；I2 = 70%，p < 0.01）。按男性比例、研究环境和样本量进行的亚组分析得出了一致的结果。荟萃回归表明，男性比例可能是异质性的潜在来源。敏感性分析显示了总体结果的可靠性和稳定性。Begg分析（p = 0.835）和Egger分析（p = 0.847）均显示可能不存在发表偏倚。总之，在亚洲，合并哮喘的COVID-19患者可能面临更高的死亡风险，至少在非老年个体中如此。
